Acute Pain - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights:

• The Acute Pain market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch, and raised awareness.
• The emerging pipeline of acute pain contains various promising therapies expected to enter the 7MM Acute Pain market during the forecast period (2024-2034).
• The United States accounts for the largest Acute Pain market size, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• The International Association for the Study of Pain (IASP) defines acute pain as sudden, sharp pain signaling a threat or disease. It arises from injury, surgery, illness, trauma, or medical procedures, typically lasting from minutes to less than 6 months and subsiding with treatment or healing.
• In 2023, postoperative pain, trauma pain, and acute medical illness accounted for ~40%, ~40%, and ~20% of diagnosed incident cases of acute pain in the United States, respectively.
• In February 2024, AFT Pharmaceuticals disclosed the launch of Maxigesic IV, the intravenous variant of its pain relief medication, in the United States through its licensee, Hikma Pharmaceuticals.
• Some of the approved Acute Pain therapies include Hyloris Pharmaceuticals/AFT Pharmaceuticals (MAXIGESIC), Formosa Pharmaceuticals (APP13007), and others.
• Emerging Drugs are - Vertex Pharmaceuticals (suzetrigine), Taiwan Liposome Company (ropivacaine liposomal), Vivozon (opiranserin) and others.
• DelveInsight's "Acute Pain Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Acute Pain, historical and forecasted epidemiology as well as the Acute Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
• Acute Pain market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Acute Pain market size from 2020 to 2034. The report also covers current Acute Pain treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Acute Pain Treatment Market

Acute Pain Overview, Country-Specific Treatment Guidelines and Diagnosis

Acute pain is an umbrella term, but the most common symptoms associated with acute pain include fatigue, flu-like symptoms, insomnia, anxiety, burning, etc. Nociceptive pain is usually acute and develops in response to a specific situation. It disappears as the affected body part heals. For example, nociceptive pain from a broken ankle gets better as the ankle heals.

Diagnosis of acute pain is made using pain assessment scales, which include VAS, VRS, NPRS, MPQ, BPI, etc. Doctors diagnose the pain by discussing symptoms, the intensity and location of pain, and the history of injury, surgery, or illness. Young patients may be asked to rate their pain intensity using the faces of the pain scale.

Additional diagnostic tests might include Blood Tests, X-rays, CT scans, MRI, Ultrasounds, Dye-injection studies, and Nerve conduction studies.

Acute Pain Treatment

WHO recommends a 3-step "Pain relief ladder" for pain management, starting with non-opioid approaches, then progressing to low-dose opioids with or without adjunct therapies, and finally, higher doses or more potent opioids for moderate-to-severe pain. Variations include a "fast-track" approach for intense acute pain, movement up or down the ladder based on disease progression or healing, and a 4th step involving invasive procedures like nerve blocks and spinal stimulators.

Acute Pain Epidemiology

The Acute Pain epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Acute Pain epidemiology is segmented with detailed insights into the total incident cases, total diagnosed cases, type-specific cases, severity-specific cases, and total treated cases of acute pain.

• In 2023, total severity-specific diagnosed incident cases of acute pain in the United States comprised ~40%, ~50%, and ~10% cases for mild, moderate, and severe, respectively.
• Postoperative pain represented around 40% of the type-specific diagnosed incident cases of acute pain in the United States in 2023, making it the most prevalent category.
• DelveInsight estimates that the total incidence of cases of acute pain in the United States is expected to increase in the forecasted period.

Acute Pain Drug Chapter

The drug chapter segment of the Acute Pain market report encloses a detailed analysis of Acute Pain marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the Acute Pain pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Acute Pain Drugs

POSIMIR (bupivacaine solution): Durect Corporation

POSIMIR (bupivacaine solution) for infiltration use is a novel and proprietary product that combines the strength of 660 mg of bupivacaine base with the innovative SABER platform technology, enabling continuous sustained delivery of a non-opioid local analgesic over 3 days in adults. POSIMIR contains more bupivacaine than any other approved single-dose sustained-release bupivacaine product. POSIMIR is administered into the subacromial space under direct arthroscopic visualization at the end of the surgery, where it continuously releases bupivacaine for 72 hours or more.

ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics

ZYNRELEF (formerly known as HTX-011) (bupivacaine and meloxicam) is a fixed-dose combination of the local anesthetic bupivacaine with the non-steroidal anti-inflammatory drug (NSAID) meloxicam. The drug is approved in Europe, while an NDA in the US has been approved in January 2024. ZYNRELEF is indicated to treat somatic-postoperative pain from small- to medium-sized surgical wounds in adults.

Emerging Acute Pain Drugs

VVZ-149 (opiranserin): Vivozon

Opiranserin (VVZ-149) for injection, developed by Vivozon, is a pioneering non-narcotic analgesic targeting postoperative pain. It seeks to replace opioid analgesics by offering a safe and efficient pain management solution. Opiranserin is a multi-target drug acting on GlyT2 and 5HT2a, key in pain signal generation and regulation, providing analgesia in both the central and peripheral nervous systems. Currently, VVZ-149 is in the Phase III clinical stage of development. In February 2023, Vivozon Pharmaceuticals announced that the results of domestic Phase III clinical trials of the non-narcotic painkiller VVZ-149 (opiranserin) confirmed the analgesic efficacy and safety.

TLC590 (ropivacaine liposomal): Taiwan Liposome Company (TLC)

TLC590 (ropivacaine liposomal) is a non-opioid, BioSeizer sustained release formulation of ropivacaine designed to prolong the retention time of ropivacaine around the injection site as a drug depot, simultaneously extending its therapeutic period and reducing unwanted systemic exposure. Currently, TLC590 is being investigated in a Phase II/III clinical trial for postsurgical pain management following inguinal hernia repair.

Acute Pain Market Outlook

Key Acute Pain companies, such as Trevena, Innocoll Pharmaceuticals, Esteve, Kowa Pharmaceuticals, Mundi Pharma, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Acute Pain.

• The emerging pipeline of acute pain contains various promising therapies expected to enter the 7MM Acute Pain market during the forecast period. By 2032, among all the therapies, the highest revenue is expected to be generated by UBRELVY.
• Among all the emerging Acute Pain therapies, the lowest revenue is expected to be generated by VX-548 and TLC590.
• Growth of the acute pain market is expected to be mainly driven by the entry of novel therapies with better clinical profiles, an increase in market penetration of therapies, an upsurge in research and development, an enriched understanding of the disease, and imminent launches of the drugs.

Acute Pain Drugs Uptake

This section focuses on the uptake rate of potential Acute Pain drugs expected to be launched in the Acute Pain market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Acute Pain Activities

The Acute Pain market report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Acute Pain market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Acute Pain emerging therapies.

Acute Pain KOL Views

To keep up with the real-world scenario in current and emerging Acute Pain market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Acute Pain. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging Acute Pain therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Acute Pain Market Access and Reimbursement

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Acute Pain Market Report

• The Acute Pain market report covers a segment of key events, an executive summary, descriptive overview of Acute Pain, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country-specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Acute Pain market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Acute Pain market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Acute Pain market.

Acute Pain Market Report Insights

• Acute Pain Patient Population
• Acute Pain Therapeutic Approaches
• Acute Pain Pipeline Analysis
• Acute Pain Market Size
• Acute Pain Market Trends
• Existing and future Acute Pain Market Opportunity

Acute Pain Market Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• Acute Pain Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL's feedback on approved and emerging Acute Pain therapies
• Key Cross Competition
• Conjoint analysis
• Acute Pain Drugs Uptake
• Key Acute Pain Market Forecast Assumptions

Acute Pain Market Report Assessment

• Current Acute Pain Treatment Practices
• Acute Pain Unmet Needs
• Acute Pain Pipeline Product Profiles
• Acute Pain Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What is the growth rate of the 7MM Acute Pain treatment market?
• What was the Acute Pain market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label Acute Pain therapies?
• How would the market drivers, barriers, and future opportunities affect the Acute Pain market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Acute Pain?
• How many companies are developing therapies for the treatment of Acute Pain?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved Acute Pain therapies?

Reasons to buy:

• The Acute Pain market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Acute Pain Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Acute Pain market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current Acute Pain patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming Acute Pain companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Acute Pain market so that the upcoming Acute Pain companies can strengthen their development and launch strategy.